This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yan, W. Articles by Chen, X. Search for Related Content PubMed PubMed Citation Articles by Yan, W. Articles by Chen, X.

Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations

Center for Comparative Oncology, University of California at Davis, Davis, California

Requests for reprints: Xinbin Chen, Center for Comparative Oncology, University of California at Davis, 2128 Tupper Hall, Davis, CA 95616. Phone: 530-754-8404; Fax: 530-752-6042; E-mail: xbchen{at}ucdavis.edu.

Key Words: mutant p53 • gain-of-function • Id2 • transcriptional repression • cell transformation

Overexpression of mutant p53 is a common theme in human tumors, suggesting a tumor-promoting gain-of-function for mutant p53. To elucidate whether and how mutant p53 acquires its gain-of-function, mutant p53 is inducibly knocked down in the SW480 colon cancer cell line, which contains mutant p53(R273H/P309S), and the MIA PaCa-2 pancreatic cancer cell line, which contains mutant p53(R248W). We found that knockdown of mutant p53 markedly inhibits cell proliferation. In addition, knockdown of mutant p53 sensitizes tumor cells to growth suppression by various chemotherapeutic drugs. To determine whether a gene involved in cell growth and survival is regulated by mutant p53, gene expression profiling analysis was performed and showed that the expression level of Id2, a member of the inhibitor of differentiation (Id) family, was markedly increased upon knockdown of mutant p53. To confirm this, Northern blot analysis was performed and showed that the expression level of Id2 was regulated by various mutant p53s in multiple cell lines. In addition, we found that the Id2 promoter is responsive to mutant but not wild-type p53, and mutant p53 binds to the Id2 promoter. Consistent with these observations, expression of endogenous Id2 was found to be inhibited by exogenous mutant p53 in p53-null HCT116 cells. Finally, we showed that knockdown of Id2 can restore the proliferative potential of tumor cells inhibited by withdrawal of mutant p53. Together, these findings suggest that one mechanism by which mutant p53 acquires its gain-of-function is through the inhibition of Id2 expression. [Cancer Res 2008;68(16):6789–96]

This article has been cited by other articles:

				H.-M. Lien, H.-W. Lin, Y.-J. Wang, L.-C. Chen, D.-Y. Yang, Y.-Y. Lai, and Y.-S. Ho Inhibition of Anchorage-Independent Proliferation and G0/G1 Cell-Cycle Regulation in Human Colorectal Carcinoma Cells by 4,7-Dimethoxy-5-methyl-l,3-benzodioxole Isolated from the Fruiting Body of Antrodia camphorate Evid. Based Complement. Altern. Med., March 17, 2009; (2009) nep020v1. [Abstract] [Full Text] [PDF]